Bioarctic Neuroscience Ab

Bioarctic Ab

Bioartic Neuroscience Ab

Dag Sehlin

Lars Lannfelt

Pär Gellerfors

Hillevi Englund

Frida Ekholm Pettersson

Greta Hultqvist

Stina Syvänen

The present invention relates to a brain delivery protein, comprising a target binding antibody which binds to a target in a mammalian brain; two carrier moieties, each of which being capable of monovalent interaction with a protein expressed on a blood brain barrier (BBB) endothelial cell, wherein each of said carrier moieties is linked to a C-terminal end of the target binding antibody. The present invention moreover relates to use of such brain delivery proteins in therapy or diagnosis or for research of e.g. neurodegenerative disorders, and other brain diseases.

Brain delivery protein

The invention relates to an isolated antibody, or fragment thereof, having high affinity for human A&#x3b2; protofibrils. The invention further relates to compositions that include the antibody, or a fragment thereof, and a pharmaceutically acceptable buffer. The invention further relates to a method of preventing or treating Alzheimer's disease, which includes the step of administering to a patient having or suspected of having Alzheimer's disease such an antibody, or fragment thereof or a composition that includes the antibody or a fragment thereof.

Protofibril selective antibodies and the use thereof

The present invention pertains to the prevention, treatment and diagnosis of neurodegenerative diseases, in particular Alzheimer's disease, and other similar disease. More specifically to high affinity antibodies selective for amyloid beta protein (A&#x3b2;) in its protofibril conformation and of IgG class and IgG1 or IgG4 subclass or combinations thereof or mutations thereof, retaining high Fc receptor binding and low C1(C1q) binding, effective in clearance of A&#x3b2; protofibrils and with reduce risk of inflammation.

Growing community of inventors

Uppsala, Sweden

Dag Sehlin